Results 281 to 290 of about 241,082 (329)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Deciphering spatially confined immune evasion niches in osteosarcoma with 3-D spatial transcriptomics: a literature review. [PDF]

Front Oncol
Qiu G, Tang Y, Zuo J, Wu H, Wan Y.
europepmc   +1 more source

Leveraging diverse cell death patterns in osteosarcoma patients and identification of the function of FADS2 in osteosarcoma cells. [PDF]

Sci Rep
Bai G, Zhao S, Chen L, Zhao M, Chen W.
europepmc   +1 more source

Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma. [PDF]

Discov Oncol
Ni C, Sun Q, Yin H.
europepmc   +1 more source

Correlation Between MRI Characteristic of Osteosarcoma with 2-Year Survival Outcomes. [PDF]

Diagnostics (Basel)
Adam MNA, Mohammed Rusli ER, Hing EY, Maktar JF, Loh C, Mohamed Haflah NH, Mohd Zaki F.   +6 more
europepmc   +1 more source

Clinical presentation of bone tumours in children and young people: a systematic review and meta-analysis. [PDF]

Arch Dis Child
Liu JF, Shanmugavadivel D, Ball-Gamble A, Walker D.   +3 more
europepmc   +1 more source